<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808300</url>
  </required_header>
  <id_info>
    <org_study_id>UMPT-1</org_study_id>
    <secondary_id>H-1212-030-449</secondary_id>
    <nct_id>NCT01808300</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid.</brief_title>
  <official_title>A Randomized,Open-label,Six-sequence,Three-period,Three-treatment,Multiple Dosing Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid After Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unimed Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unimed Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, six-sequence, three-period, three-treatment, multiple dosing&#xD;
      clinical trial to investigate the pharmacokinetic drug interaction between Pregabalin and&#xD;
      Thioctic acid after oral administration in healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss / Cmax of pregabalin and thioctic acid</measure>
    <time_frame>2d (9d, 16d): 0h (predose:Thioctic acid), 12h (pre-dose:Pregabalin), 3d(10d, 17d): 0h (pre-dose), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12h, 24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ctrough,ss / Tmax,ss / t½ / CL/F of pregabalin and thioctic acid</measure>
    <time_frame>2d (9d, 16d): 0h (predose:Thioctic acid), 12h (pre-dose:Pregabalin), 3d(10d, 17d): 0h (pre-dose), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12h, 24h</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A-B-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to A-B-C sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-C-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to A-C-B sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-C-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to B-C-A sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-A-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to B-A-C sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-A-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to C-A-B sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-B-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to C-B-A sequence for 3 period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 300mg, Thioctic acid 600mg</intervention_name>
    <description>A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days&#xD;
B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days&#xD;
C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B</description>
    <arm_group_label>A-B-C</arm_group_label>
    <arm_group_label>A-C-B</arm_group_label>
    <arm_group_label>B-A-C</arm_group_label>
    <arm_group_label>B-C-A</arm_group_label>
    <arm_group_label>C-A-B</arm_group_label>
    <arm_group_label>C-B-A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body weight ae least 50kg and BMI(body mass index) within the range of 18 to 27kg/m2&#xD;
&#xD;
          2. Provision of signed written informed consent&#xD;
&#xD;
          3. Acceptable physical examination and clinical examination, during screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A subject with clinical evidence or history of hepatic (including carrier of hepatitis&#xD;
             virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic,&#xD;
             oncologic, psychiatric, or cardiovascular disease&#xD;
&#xD;
          2. A subject with a history of gastrointestinal disease or surgery (except simple&#xD;
             appendectomy or repair of hernia), which can influence the absorption of the study&#xD;
             drug&#xD;
&#xD;
          3. A subject with history of allergies including study drug (pregabalin or thioctic acid)&#xD;
             or other drug allergies (aspirin, antibiotics, etc.), or history of clinically&#xD;
             significant allergies&#xD;
&#xD;
          4. A subject whose lab test results are as follows: AST(SGOT), ALT(SGPT) &gt; 1.5 x upper&#xD;
             limit of reference range&#xD;
&#xD;
          5. Presence or history of drug abuse or positive result in urine drug screening test&#xD;
&#xD;
          6. Use any prescriptive medication, Korean traditional medication not considered&#xD;
             acceptable by the clinical investigator during the last 14 days period before first&#xD;
             dosing, or use any OTC medication not considered acceptable by the clinical&#xD;
             investigator during the last 7 days period before first dosing (if used medication is&#xD;
             considered acceptable by investigator, patients can be included)&#xD;
&#xD;
          7. Participation in clinical trials of any drug within 60 days prior to the participation&#xD;
             of the study&#xD;
&#xD;
          8. Blood donation during 2 months or apheresis during 1 month before the study&#xD;
&#xD;
          9. Use of alcohol over 21 units/weeks&#xD;
&#xD;
         10. Smoker who smoke more than 10 cigarettes per day or who cannot stop smoking during the&#xD;
             study period (from 24 hours before hospitalization to discharge)&#xD;
&#xD;
         11. Use of caffeine drink during the study period(from 24 hours before hospitalization to&#xD;
             discharge)&#xD;
&#xD;
         12. A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products&#xD;
             during the study&#xD;
&#xD;
         13. Judged to be inappropriate for the study by the investigator after reviewing clinical&#xD;
             laboratory results or other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>March 3, 2013</study_first_submitted>
  <study_first_submitted_qc>March 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

